* Fennec Pharmaceuticals Inc is expected to show a rise in quarterly revenue when it reports results on May 9 (estimated) for the period ending March 31 2024
* The Research Triangle Park North Carolina-based company is expected to report a 1,025.6% increase in revenue to $18.876 million from $1.68 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Fennec Pharmaceuticals Inc is for earnings of 26 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had fallen by about 40.0% in the last three months.
* Wall Street's median 12-month price target for Fennec Pharmaceuticals Inc is $18.00, above its last closing price of $9.09.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.05 -0.02 -0.10 Missed -410.2
Sep. 30 2023 -0.12 -0.12 -0.07 Beat 41.7
Jun. 30 2023 -0.17 -0.16 -0.21 Missed -34.2
Mar. 31 2023 -0.21 -0.21 -0.23 Missed -9.6
Dec. -0.20 -0.26 -0.26 Met 1.8
31 2022
Sep. 30 2022 -0.18 -0.18 -0.31 Missed -70.6
Jun. 30 2022 -0.15 -0.14 -0.19 Missed -39
Mar. 31 2022 -0.13 -0.14 -0.14 Met 0
This summary was machine generated May 7 at 14:55 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments